RxDoctor Payments DataLook up a doctor →

Bruce Torkan, MD

General Practice · Los Angeles, CANPI 1699770321

Payments from drug & device makers

$3,789,621in general payments, 2019–2025

Across 555 payments — averaging $6828.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$981K
  • Eli Lilly$897K
  • E.r. Squibb & Sons, L.L.C.$456K
  • Gilead$380K
  • Adamis Pharmaceuticals Corporation$279K
  • Taro Pharmaceuticals USA, Inc.$242K
  • plus $555K from 42 others
$449in research payments, 2019–2025

Across 1 payment — averaging $449.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$449

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,789,621 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$253,679
Medicare patients
165
Services billed
3,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other general practice in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →